Table 1 Clinical characteristics of the patients with LUAD used in this study

Time

 Mean ± SD

909.60 ± 892.04

1578.13 ± 1087.35

1220.31 ± 1041.95

 Median[min–max]

658.00 [4.00,7248.00]

1410.00 [0.90,6120.00]

900.00 [0.90,7248.00]

State

1.10*10^–7

4.50*10^–7

 Alive

326 (34.24%)

207 (21.74%)

533 (55.99%)

 Dead

183 (19.22%)

236 (24.79%)

419 (44.01%)

Age

 Mean ± SD

65.29 ± 10.03

64.42 ± 10.10

64.88 ± 10.07

 Median[min–max]

66.00 [33.00,88.00]

65.00 [33.00,87.00]

65.50 [33.00,88.00]

Sex

0.22

0.33

 Female

274 (28.78%)

220 (23.11%)

494 (51.89%)

 Male

235 (24.68%)

223 (23.42%)

458 (48.11%)

T

0.17

0.33

 T1

171 (17.96%)

150 (15.76%)

321 (33.72%)

 T2

272 (28.57%)

251 (26.37%)

523 (54.94%)

 T3

45 (4.73%)

28 (2.94%)

73 (7.67%)

T4

18 (1.89%)

12 (1.26%)

30 (3.15%)

 TX

3 (0.32%)

0 (0.0e + 0%)

3 (0.32%)

 NA

0 (0.0e + 0%)

2 (0.21%)

2 (0.21%)

N

0.06

0.18

 N0

329 (34.56%)

299 (31.41%)

628 (65.97%)

 N1

97 (10.19%)

88 (9.24%)

185 (19.43%)

 N2

70 (7.35%)

53 (5.57%)

123 (12.92%)

 N3

2 (0.21%)

0 (0.0e + 0%)

2 (0.21%)

 NA

0 (0.0e + 0%)

2 (0.21%)

2 (0.21%)

 NX

10 (1.05%)

1 (0.11%)

11 (1.16%)

 NA

1 (0.11%)

0 (0.0e + 0%)

1 (0.11%)

M

4.20*10^–200

2.50*10^–199

 M0

341 (35.82%)

0 (0.0e + 0%)

341 (35.82%)

 M1

17 (1.79%)

0 (0.0e + 0%)

17 (1.79%)

 M1a

2 (0.21%)

0 (0.0e + 0%)

2 (0.21%)

 M1b

5 (0.53%)

0 (0.0e + 0%)

5 (0.53%)

 MX

140 (14.71%)

0 (0.0e + 0%)

140 (14.71%)

NA

4 (0.42%)

443 (46.53%)

447 (46.95%)

Stage

6.30*10^–198

3.10*10^–197

 Stage I

273 (28.68%)

0 (0.0e + 0%)

273 (28.68%)

 Stage II

122 (12.82%)

0 (0.0e + 0%)

122 (12.82%)

 Stage III

81 (8.51%)

0 (0.0e + 0%)

81 (8.51%)

 Stage IV

25 (2.63%)

0 (0.0e + 0%)

25 (2.63%)

 NA

8 (0.84%)

443 (46.53%)

451 (47.37%)